Mylan is planning to acquire around 29 per cent of Matrix Labs at a price of up to Rs 150 per share. Mylan holds around 71.16 per cent in Matrix through MP Laboratories of Mauritius. At the price of ...

The battle over generic rights to Pfizer's blockbuster blood pressure pill Norvasc slogs on, with a new chalk mark in favor of Mylan Laboratories. First, a short recap. Mylan has been selling ...

N E W   Y O R K, Nov. 29 -- The Federal Trade Commission approved a $100 million settlement with Mylan Laboratories, the largest monetary settlement in the commission’s history. The agency ...

Mylan to acquire DPT Laboratories’ parent in $1B deal. By Staff Writer Updated May 23, 2016 6:21 p.m. ... Renaissance Acquisition Holdings LLC, by global pharmaceutical company Mylan.

PITTSBURGH and MUMBAI, India, May 27, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it plans to rebrand its Hyderabad, India-based subsidiary Matrix Laboratories Limited as Mylan.

Mylan to pay $135 million July 12, 2000: 5:08 p.m. ET Pharmaceutical company agrees to settle FTC anti-monopoly suit over anxiety drugs ...

In 2007, the entrepreneur-promoter, Mr Nimmagadda Prasad, sold it to Mylan Laboratories in what was termed a ‘big deal' ( Rs 3,434 crore for 71.5 per cent equity) for Indian pharma.